1. Bradford A Youngblood, John Leung, Rustom Falahati, Jason Williams, Julia Schanin, Emily C Brock, Bhupinder Singh, Alan T Chang, Nenad Tomasevic, Christopher R Bebbington. Discovery, Function, and Therapeutic Targeting of Siglec-8. Cells. 2020 Dec 24;10(1):19.
Siglecs (sialic acid-binding immunoglobulin-like lectins) are single-pass cell surface receptors that have inhibitory activities on immune cells. Among these, Siglec-8 is a CD33-related family member selectively expressed on human mast cells and eosinophils, and at low levels on basophils. These cells can participate in inflammatory responses by releasing mediators that attract or activate other cells, contributing to the pathogenesis of allergic and non-allergic diseases. Since its discovery in 2000, initial in vitro studies have found that the engagement of Siglec-8 with a monoclonal antibody or with selective polyvalent sialoglycan ligands induced the cell death of eosinophils and inhibited mast cell degranulation. Anti-Siglec-8 antibody administration in vivo to humanized and transgenic mice selectively expressing Siglec-8 on mouse eosinophils and mast cells confirmed the in vitro findings, and identified additional anti-inflammatory effects.
1μg (R: reducing condition, N: non-reducing condition).
您现在的位置：